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Cholesterol plays an important role in the HIV life cycle,
and cholesterol depletion impairs both production and
infectivity of HIV virions. Such dependence on cholesterol
suggests that HIV may have evolved mechanisms to
ensure access to cellular cholesterol during viral assembly.
Recently, we demonstrated that HIV-1, via its protein Nef,
inhibits activity of the cellular cholesterol transporter
ABCA1 and impairs reverse cholesterol transport (RCT)
from infected cells. In this study, we examined interaction
between Nef and ABCA1 and investigated the role of
ABCA1 in cholesterol delivery to nascent HIV virions.
ABCA1 is a 12-transmembrane domain protein, and co-
immunoprecipitation analysis using Nef and various frag-
ments of ABCA1 identified multiple sites of interaction.
Importantly, Nef was found to interact with the 46-ami-
noacid carboxyl-terminal domain of ABCA1, which was
previously implicated in RCT. Mutation of leucines to
alanines in positions 2230, 2233 and 2235 impaired
interaction of this C-terminal domain of ABCA1 with Nef.
When these mutations were introduced in the full-length
ABCA1, such mutant protein was able to support RCT but
lost sensitivity to Nef. To further characterize the role of
ABCA1 inhibition in HIV biology, we analyzed choles-
terol content of lipid rafts and HIV virions produced in
cells expressing or not ABCA1. This analysis demonstrated
that ABCA1 expression significantly reduced lipid raft
cholesterol content, resulting in a corresponding reduc-
tion of virus-associated cholesterol and viral infectivity.
This result is consistent with ABCA1-mediated redirection
of cholesterol from lipid rafts (sites of HIV assembly) to
non-raft regions of the plasma membrane (physiological
localization of ABCA1). Intriguingly, Nef expression
induced re-localization of ABCA1 to lipid rafts, suggesting
that HIV hijacks the ABCA1 pathway to deliver cholesterol
to the sites of HIV assembly.
Conclusion
Our results describe a novel interaction between HIV-1
Nef and ABCA1, the key cholesterol transporter of periph-
eral cells. We demonstrate that interaction of Nef with the
C-terminal domain of ABCA1 is critical for Nef-mediated
impairment of RCT. Intriguingly, Nef seems to hijack
ABCA1 to deliver cholesterol to HIV assembly sites. It
appears that in an infected cell there is a dynamic interac-
tion between Nef and ABCA1: overexpression of Nef (a
situation occurring in most HIV-infected cells) leads to
inactivation of ABCA1 physiological activity (RCT), its re-
localization to lipid rafts, delivery of cholesterol to assem-
bling virions and production of highly infectious viral
particles. In contrast, overexpression of ABCA1 (e.g., by
drugs stimulating ABCA1 expression such as LXR ago-
nists) stimulates RCT, reduces cholesterol in lipid rafts
and virions, and inhibits HIV production and infectivity.
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